Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals Inc (INM)

Inmed Pharmaceuticals Inc (INM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,645
  • Shares Outstanding, K 16,267
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,200 K
  • 60-Month Beta 0.55
  • Price/Sales 9.82
  • Price/Cash Flow N/A
  • Price/Book 0.62
Trade INM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.22
  • Most Recent Earnings -0.25 on 05/13/22
  • Next Earnings Date 05/12/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.22
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +51.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4173 +12.63%
on 06/16/22
0.7700 -38.96%
on 06/02/22
-0.2750 (-36.91%)
since 06/01/22
3-Month
0.4173 +12.63%
on 06/16/22
1.4200 -66.90%
on 04/21/22
-0.4556 (-49.22%)
since 04/01/22
52-Week
0.4173 +12.63%
on 06/16/22
3.2000 -85.31%
on 07/06/21
-2.6362 (-84.87%)
since 07/01/21

Most Recent Stories

More News
InMed Pharmaceuticals (NASDAQ: INM) Announces Results of Peer-Reviewed Study

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has had its peer-reviewed scientific study published in the “International...

INM : 0.4700 (-0.09%)
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the...

INM : 0.4700 (-0.09%)
Stocks in play: InMed Pharmaceuticals Inc.

Announced it has launched B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin ...

INM : 0.4700 (-0.09%)
Top 5 Ways to Profit from a Potential THCV Boom

THCV, or tetrahydrocannabivarin may have the potential to help with energy, focus/attention, and even appetite, weight/BMI, according to InMed Pharmaceuticals Inc.’s (NASDAQ: INM). In addition, according...

INM : 0.4700 (-0.09%)
TLRY : 3.15 (+0.96%)
TLRY.TO : 4.02 (+0.25%)
WEED.TO : 3.63 (-0.82%)
CGC : 2.81 (-1.40%)
JAZZ : 158.58 (+1.65%)
ABBV : 153.80 (+0.42%)
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

Produces highly pure d9-dominant THCV, a non-intoxicating cannabinoidBolsters Company’s commercial portfolio, which also includes CBDV, CBC and CBTTHCV has...

INM : 0.4700 (-0.09%)
InMed Pharmaceuticals (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private...

INM : 0.4700 (-0.09%)
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

VANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the...

INM : 0.4700 (-0.09%)
InMed Pharmaceuticals (NASDAQ: INM) Announces $5M Registered Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements...

INM : 0.4700 (-0.09%)
InMed Pharmaceuticals (NASDAQ: INM) Announces Q3 Fiscal 2022 Financial Results

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced financial results for the third quarter...

INM : 0.4700 (-0.09%)
InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates

InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -8.70% and 27.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

INM : 0.4700 (-0.09%)
MEIP : 0.5800 (-4.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC.

See More

Key Turning Points

3rd Resistance Point 0.5253
2nd Resistance Point 0.5103
1st Resistance Point 0.4901
Last Price 0.4700
1st Support Level 0.4549
2nd Support Level 0.4399
3rd Support Level 0.4197

See More

52-Week High 3.2000
Fibonacci 61.8% 2.1370
Fibonacci 50% 1.8087
Fibonacci 38.2% 1.4803
Last Price 0.4700
52-Week Low 0.4173

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar